Mesigyna

Subscribe to Selected New Research on Mesigyna

12 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: contains 50 mg norethisterone enanthate and 5 mg estradiol valerate in an oily solution

Also Known As:

HRP 102; HRP-102; HRP102; 19-Norpregn-4-en-20-yn-3-one, 17-((1-oxoheptyl)oxy)-, (17alpha)-, mixt. with (17beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Hemorrhage 03/01/1995 - "These findings show that Mesigyna users experienced better cycle control and more acceptable bleeding patterns than did the users of the other two injectables." 05/01/2000 - "The incidence of bleeding anomalies was higher in the Mesigyna group, with a discontinuation rate for these reasons of 20% versus 4% for IUD (p <0.05)" 05/01/2000 - "The duration of bleeding days as well as dysmenorrhea were less with Mesigyna" 05/01/2000 - "Mean weight gain after one year of use was 1.02 kg. Mesigyna is an appropiate once-a-month injectable contraceptive for Latin American women since it is highly effective and its perception of normal menstrual bleeding is of importance in the Latin American population." 04/01/1994 - "Studies show that users of 2 once-a-month injectables, Cyclofem and Mesigyna, experience bleeding patterns that digress somewhat from normal menstrual patterns" Get all the results and reference details, order at left...
2.	Amenorrhea 04/01/1996 - "Two combined injectable preparations--Cyclofem and Mesigyna--are now available in many countries and associated with a significant reduction in both amenorrhea and unacceptable bleeding rates" 08/01/1999 - "Discontinuation rates because of amenorrhea were 2.74 in the Cyclofem group compared to 1.38 in the Mesigyna group, whereas the rates of discontinuation because bleeding problems were significantly higher among Mesigyna users (11.54) compared to the Cyclofem group (7.39)" 04/01/1994 - "Researchers find lower 12-month life table discontinuation rates for menstrual disturbances for Cyclofem (2.1-5.2% for amenorrhea and 6.3-12.7% for bleeding related reasons) and Mesigyna (0.8-4.2% for amenorrhea and 7.5-12% for bleeding related reasons) than expected for most progestogen-only methods" 01/01/1988 - "Discontinuations for bleeding irregularities were low, being 6.3% and 7.5% for HRP112 and HRP102 respectively, as well as for 'amenorrhea', the respective figures being 2.1% and 1.6%" 03/01/1995 - "Discontinuation rates for bleeding problems were significantly different between the groups: discontinuation rates for amenorrhea were 0.58%, 3.71% and 0.68% (p < 0.001) for Mesigyna, Cyclofem and Injectable No. 1; for other bleeding problems, the rates were 4.88%, 8.38% and 12.64% (p < 0.001)" Get all the results and reference details, order at left...
3.	Metrorrhagia (Spotting) 03/01/1995 - "Cyclofem users had more spotting days than did Mesigyna users in each 90-day period (5-8 vs. 5-6)" 05/01/1985 - "The percentage of days with bleeding and spotting was 24% for Cycloprovera and 29% for HRP-102" Get all the results and reference details, order at left...
4.	Weight Gain 05/01/2000 - "Mean weight gain after one year of use was 1.02 kg. Mesigyna is an appropiate once-a-month injectable contraceptive for Latin American women since it is highly effective and its perception of normal menstrual bleeding is of importance in the Latin American population." Get all the results and reference details, order at left...
5.	Dysmenorrhea (Menstrual Pain) 05/01/2000 - "The duration of bleeding days as well as dysmenorrhea were less with Mesigyna" Get all the results and reference details, order at left...
5 Diseases and 12 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	CycloProvera
2.	Injectable No. 1
3.	Medroxyprogesterone 17-Acetate (Depo-Provera)
4.	Estradiol (Estrace)
5.	Contraceptive Agents (Contraceptives)
6.	N,N-dimethyl-4-anisidine (DMPA)
7.	estradiol 17 beta-cypionate (Depo-estradiol)
7 Drugs and Important Bio-Agents and 10 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Intrauterine Devices (Intrauterine Device)
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>